Akademik Veri Yönetim Sistemi
Duzce Medical Journal, cilt.12, sa.1, ss.104-108, 2010 (Scopus)
Mycophenolate mofetil (MMF) is an immunosuppressive agent that has been shown to be effective in transplant patients. It is also efficacious in the management of lupus nephritis, and useful in the treatment of autoimmune conditions as its mechanisms of action target the T- and B - lymphocytes, leading to suppression of the cell-mediated 3immune responses and antibody formation. It has been used successfully in immune-mediated conditions like myasthenia gravis, autoimmune hepatitis and immune cytopenias. However, its optimal use in non-renal manifestations (hematological, neuropsychiatric, myocardial, pulmonary, cutaneous etc.) in lupus patients is unclear. There are yet to be randomised controlled trials to guide the optimal doses and durations of MMF in such situations. MMF is well tolerated and safe to use, though there are reports of serious adverse effects like urticaria, myopathy, Epstein-Barr virus-associated B-cell lymphoma, cytomegalovirus infections and disseminated varicella zoster. Another area of concern for patients is the increased cost of using long-term MMF. © 2010 Düzce Medical Journal.